Literature DB >> 6280538

Etidronate disodium in the treatment of Paget's disease of bone.

S M Krane.   

Abstract

Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with this drug has to be set against adverse effects, of which pain is probably the most bothersome in practice. Clinical remission can last as long as 2 years after treatment is stopped.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280538     DOI: 10.7326/0003-4819-96-5-619

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Drug treatments for relief of pain due to bone metastases.

Authors:  G W Hanks
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

2.  Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine.

Authors:  C R Paterson; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-21

3.  Paget's disease of bone.

Authors:  G J Strewler
Journal:  West J Med       Date:  1984-05

4.  Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.

Authors:  S J Wimalawansa; R D Gunasekera
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

Review 5.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

6.  Use of zoledronic acid in the treatment of Paget's disease.

Authors:  Margaret Seton; Stephen M Krane
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

7.  Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway.

Authors:  Ye Zhao; Hui-Ling Wang; Tong-Tong Li; Fei Yang; Chi-Meng Tzeng
Journal:  Drug Des Devel Ther       Date:  2020-01-15       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.